Showing results (231-240 of 241) with videos related to
Sort By:
Pageof 25
Journal of Great Lakes Research|July 24, 2018
Ecosystem services in the Great LakesAlan D Steinman, Bradley J Cardinale, Wayne R Munns, et al.Journal of Medicinal Chemistry|May 17, 2002
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonistsEdward K Dziadulewicz, Timothy J Ritchie, Allan Hallett, et al.Vaccine|November 18, 2022
Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national studyNusrat Homaira, Roxanne Strachan, Helen Quinn, et al.The Journal of Infectious Diseases|February 24, 2025
Comparison of the incidence and risk factors of COVID-19 and influenza associated acute respiratory illnesses: Results of the SHIVERS-II, III, IV prospective community cohort studyQ Sue Huang, Tim Wood, Nayyereh Aminisani, et al.Plos Medicine|June 3, 2024
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedulesAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.Nature Communications|November 11, 2024
Spatial and temporal transmission dynamics of respiratory syncytial virus in New Zealand before and after the COVID-19 pandemicLauren Jelley, Jordan Douglas, Meaghan O'Neill, et al.Journal of Medicinal Chemistry|January 20, 2006
Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic painAndrew J Culshaw, Stuart Bevan, Martin Christiansen, et al.MMWR. Morbidity and Mortality Weekly Report|October 3, 2024
Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024Erica E Zeno, Francisco Nogareda, Annette Regan, et al.The Journal of Infectious Diseases|January 28, 2004
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months oldRobert B Belshe, Frances K Newman, Theodore F Tsai, et al.Influenza and Other Respiratory Viruses|February 13, 2024
Impact of the COVID-19 related border restrictions on influenza and other common respiratory viral infections in New ZealandQ Sue Huang, Nikki Turner, Tim Wood, et al.Pageof 25